Helius Medical Technologies, Inc. to Present at the Benzinga Healthcare Small Cap Conference
23 September 2021 - 6:05AM
Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the
“Company”), a neurotech company focused on neurological wellness,
today announced that Dane C. Andreeff, President and Chief
Executive Officer, will present at the Benzinga Healthcare Small
Cap Conference as follows:
Date: |
Wednesday,
September 29, 2021 |
Time: |
1:35PM ET |
Webcast: |
September 29 Track 2 - Livestream - Benzinga Small Cap
Conference |
The presentation will be webcast live at the
aforementioned time, and archived for 30 days thereafter, via the
Company’s website at www.heliusmedical.com, under the Investors
Relations section.
About Helius Medical Technologies,
Inc.
Helius Medical Technologies is a neurotech company
focused on neurological wellness. The Company’s purpose is to
develop, license and acquire unique and non-invasive platform
technologies that amplify the brain’s ability to heal itself. The
Company’s first commercial product is the Portable Neuromodulation
Stimulator (PoNS™). For more information, visit
www.heliusmedical.com.
About the PoNS™ Device and PoNS
Treatment™
The Portable Neuromodulation Stimulator (PoNS™) is
an innovative non-surgical device, inclusive of a controller and
mouthpiece, which delivers electrical stimulation to the surface of
the tongue to provide treatment of gait deficit. The PoNS device is
indicated for use in the United States as a short term treatment of
gait deficit due to mild-to-moderate symptoms from multiple
sclerosis (“MS”) and is to be used as an adjunct to a supervised
therapeutic exercise program in patients 22 years of age and over
by prescription only. PoNS is authorized for sale in Canada for two
indications: PoNS is authorized as short term treatment (14 weeks)
of chronic balance deficit due to mild-to-moderate traumatic brain
injury and is to be used in conjunction with physical
therapy. PoNS is authorized for use as a short term treatment
(14 weeks) of gait deficit due to mild and moderate symptoms from
Multiple Sclerosis (MS) and is to be used in conjunction with
physical therapy. The PoNS™ is an investigational medical
device in the Australia (“AUS”) and is currently under premarket
review by the AUS Therapeutic Goods Administration.
Investor Relations Contact:Lisa M.
Wilson, In-Site Communications, Inc.T: 212-452-2793E:
lwilson@insitecony.com
Helius Medical Technolog... (NASDAQ:HSDT)
Historical Stock Chart
From Apr 2024 to May 2024
Helius Medical Technolog... (NASDAQ:HSDT)
Historical Stock Chart
From May 2023 to May 2024